Keros Therapeutics Inc (KROS)

04:46 AM

What drives Keros Therapeutics Inc. stock priceExceptional ROI - PrintWeekIndia

04:46 AM

03:58 AM

What analysts say about Keros Therapeutics Inc. stockTremendous return on equity - PrintWeekIndia

03:58 AM

04:49 AM

Published on: 2025-07-25 08:18:27 - Autocar Professional

04:49 AM

01:39 AM

Is Keros Therapeutics Inc. a good long term investmentRapid portfolio appreciation - PrintWeekIndia

01:39 AM

Jul 24, 2025

How high can Keros Therapeutics Inc. stock price go in 2025Consistent high-performance stocks - jammulinksnews.com

Jul 24, 2025

Jul 22, 2025

Keros Therapeutics Inc. Stock Analysis and ForecastTriple-digit profit margins - jammulinksnews.com

Jul 22, 2025

Jul 19, 2025

(KROS) Trading Signals - news.stocktradersdaily.com

Jul 19, 2025

Jul 18, 2025

Should I buy Keros Therapeutics Inc. stock before earningsHigh Confidence Trade Setups - Newser

Jul 18, 2025

Jul 17, 2025

Keros Therapeutics Begins Phase 3 Trial for Elritercept - TipRanks

Jul 17, 2025

Jul 17, 2025

Keros Therapeutics doses first patient in Phase 3 MDS trial By Investing.com - Investing.com South Africa

Jul 17, 2025

Jul 17, 2025

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept - The Manila Times

Jul 17, 2025

Jul 17, 2025

Keros Therapeutics doses first patient in Phase 3 MDS trial - Investing.com

Jul 17, 2025

Jul 16, 2025

Why Keros Therapeutics Inc. stock attracts strong analyst attentionLow Drawdown Trade Signals - Newser

Jul 16, 2025

Jul 16, 2025

How Keros Therapeutics Inc. stock performs during market volatilityFree Signals Group - Newser

Jul 16, 2025

Jul 15, 2025

What makes Keros Therapeutics Inc. stock price move sharplyFree Trading Strategy Suggestions - Newser

Jul 15, 2025

Jul 09, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $30.56 Average Target Price from Brokerages - MarketBeat

Jul 09, 2025

Jul 09, 2025

Trend Tracker for (KROS) - news.stocktradersdaily.com

Jul 09, 2025

Jul 08, 2025

Sarcopenia Market Expected to Experience Major Growth by 2034, According to DelveInsight | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross - Barchart.com

Jul 08, 2025

Jul 06, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Jul 06, 2025

Jun 30, 2025

Keros Therapeutics, Inc.(NasdaqGM: KROS) dropped from Russell 3000 Growth Index - MarketScreener

Jun 30, 2025

Jun 30, 2025

Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Value Index - MarketScreener

Jun 30, 2025

Jun 18, 2025

(KROS) Trading Report - news.stocktradersdaily.com

Jun 18, 2025

Jun 17, 2025

Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - MSN

Jun 17, 2025

Jun 16, 2025

Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace

Jun 16, 2025

Jun 14, 2025

Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $30.56 - MarketBeat

Jun 14, 2025